ArticleEuropean journal of pediatrics2011
Omalizumab in the treatment of eosinophilic esophagitis and food allergy.
Article in European journal of pediatrics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 2 syntheses or guidelines pooled it, 153 citations in OpenAlex.
- Eosinophilic esophagitis in children and adolescents: a clinical practice guideline.Italian journal of pediatrics · 2025Guideline
- Meta-Analysis-Based Guidance for Dietary Management in Eosinophilic Esophagitis.Current gastroenterology reports · 2015Pooled it
- A pilot study of omalizumab in eosinophilic esophagitis.PloS one · 2015Trial
- Real-life lessons on omalizumab and food allergy: The potential for unexplored outcomes.The World Allergy Organization journal · 2026Review
- Circulating Food Allergen-Specific Antibodies, Beyond IgG4, Are Elevated in Eosinophilic Esophagitis.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025Article
- Mouse models of eosinophilic esophagitis: molecular and translational insights.American journal of physiology. Gastrointestinal and liver physiology · 2025Review
- Current and Emerging Therapies for Eosinophilic Esophagitis (EoE): A Comprehensive Review.Pharmaceutics · 2025Review
- Therapeutic monoclonal antibodies in allergy: Targeting IgE, cytokine, and alarmin pathways.Immunological reviews · 2024Review
- Eosinophilic esophagitis and inhalant antigens: Pointing out the roles of allergic rhinitis, immunotherapy and biologic treatment.The World Allergy Organization journal · 2024Review
- Animal models of eosinophilic esophagitis.Journal of leukocyte biology · 2024Review
- Article
- Omalizumab for the reduction of allergic reactions to foods: a narrative review.Frontiers in allergy · 2024Review
- The ontogenesis and heterogeneity of basophils.Discovery immunology · 2024Review
- Food Allergy Characteristics Associated With Coexisting Eosinophilic Esophagitis in FARE Registry Participants.The journal of allergy and clinical immunology. In practice · 2023Article
- EoE behaves as a unique Th2 disease: a narrative review.Translational gastroenterology and hepatology · 2023Review
- The rationale for development of ligelizumab in food allergy.The World Allergy Organization journal · 2022Review
- Immune system and microbiome in the esophagus: implications for understanding inflammatory diseases.The FEBS journal · 2022Review
- Induction of Severe Eosinophilic Esophagitis and Multi-Organ Inflammation by Airborne Allergens is Associated with IL-4/IL-13 and CCL11 but Not IgE in Genetic Susceptible Mice.Journal of inflammation research · 2022Article
- Molecular Mechanisms of Eosinophilic Esophagitis.International journal of molecular sciences · 2021Review
- Eosinophilic esophagitis: clinical, endoscopic, histologic and therapeutic differences and similarities between children and adults.Therapeutic advances in gastroenterology · 2021Review
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Omalizumab is currently used in severe asthma and has been tried in other allergic disorders. The authors report two patients with multiple food allergies and eosinophilic esophagitis on a very restrictive diet who have been treated with omalizumab, in order to improve food intolerance--the major distressing factor in their lives. The patients significantly improved in the reported symptoms. However, no improvement was seen regarding esophageal endoscopy and histology. Given the poor histological and endoscopy response, eosinophilic esophagitis persistence is unlikely to be IgE dependent. Omalizumab may improve the quality of life of patients with severe food allergy by improving symptoms, but it does not appear to change endoscopic and histological features of eosinophilic esophagitis in a short follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.